This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...
On November 28, 2025, the U.S. Food and Drug Administration (FDA) withdrew its 2024 proposed rule entitled “Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback